Technical Analysis for ACET - Adicet Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical ACET trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bullish? | Reversal | -1.93% | |
| Stochastic Reached Oversold | Weakness | -1.93% | |
| Wide Bands | Range Expansion | -1.93% | |
| Down 3 Days in a Row | Weakness | -1.93% | |
| Oversold Stochastic | Weakness | -1.93% | |
| Death Cross | Bearish | -2.01% | |
| NR7 | Range Contraction | -2.01% | |
| Doji - Bullish? | Reversal | -2.01% | |
| Wide Bands | Range Expansion | -2.01% | |
| Fell Below 200 DMA | Bearish | -3.47% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 5% | about 1 hour ago |
| Down 3% | about 1 hour ago |
| Down 2 % | about 2 hours ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 2 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 04/10/2020
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Diseases Immune System Antibodies Cancer Immunotherapy Therapies For Cancer Immune Response Chimeric Antigen Receptor Adoptive Cell Transfer Chimeric Antigen Receptor T Cell T Cell Antigen
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Diseases Immune System Antibodies Cancer Immunotherapy Therapies For Cancer Immune Response Chimeric Antigen Receptor Adoptive Cell Transfer Chimeric Antigen Receptor T Cell T Cell Antigen
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.7 |
| 52 Week Low | 9.71 |
| Average Volume | 129,337 |
| 200-Day Moving Average | 13.96 |
| 50-Day Moving Average | 13.92 |
| 20-Day Moving Average | 13.97 |
| 10-Day Moving Average | 14.42 |
| Average True Range | 1.03 |
| ADX | 16.61 |
| +DI | 18.79 |
| -DI | 23.47 |
| Chandelier Exit (Long, 3 ATRs ) | 13.06 |
| Chandelier Exit (Short, 3 ATRs ) | 14.85 |
| Upper Bollinger Band | 16.45 |
| Lower Bollinger Band | 11.50 |
| Percent B (%b) | 0.34 |
| BandWidth | 35.43 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.17 |
| MACD Histogram | -0.1672 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.53 | ||||
| Resistance 3 (R3) | 14.61 | 14.24 | 14.31 | ||
| Resistance 2 (R2) | 14.24 | 13.90 | 14.20 | 14.23 | |
| Resistance 1 (R1) | 13.72 | 13.69 | 13.98 | 13.64 | 14.16 |
| Pivot Point | 13.34 | 13.34 | 13.48 | 13.31 | 13.34 |
| Support 1 (S1) | 12.82 | 13.00 | 13.08 | 12.74 | 12.22 |
| Support 2 (S2) | 12.45 | 12.79 | 12.41 | 12.15 | |
| Support 3 (S3) | 11.92 | 12.45 | 12.07 | ||
| Support 4 (S4) | 11.85 |
